Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

Background: HER2 (Human epidermal growth factor receptor 2) activation has been associated with poor prognosis in a number of tumours as breast, gastric and lung cancers, but the prognostic role of HER2 in colorectal cancer (CRC) remains unclear.Objective: The aim of the current work was to detect the incidence and prognostic impact of HER2 overexpression in metastatic CRC patients in relation to clinico-pathologic features and outcome.Patients and Methods: Data of metastatic CRC patients treated from January 2012 to end of December 2016 in a tertiary referral university hospital were collected. Eligible patients had their paraffin block tested for HER2.Results: Clinico-pathologic features of 70 patients were available for analysis. Age ranged 20-73 years, at a median of 39.5 years. Fifty (71.4%) of these cases were left sided. Male to female ratio was 3:4. Mucinous variant was present in 27.1 %( 19 cases). Synchronous metastasis constituted 61.4%. HER2 incidence was found in 8.57% (6 cases). Her2 positivity was significantly associated with a shorter time to progression on both first line of therapy, PFS1 (mPFS1 3 vs. 6 months, p=0.045) and PFS2 (mPFS2 4 vs.6 months, p=0.036). No significant relation to clinico-pathological characteristics or OS were detected. Conclusion:HER2 positivity was not associated with clinico-pathologic features but was related to outcome with a shorter PFS but not OS in metastatic CRC. Further prospective data sets are required to confirm its prognostic role.

Introduction: Gastric cancer is the 3rd cause of cancer related deaths worldwide. In Egypt, it is 12th in position regarding incidence and cancer-related deaths. About 65% of patients present with locally advanced or metastatic disease with 5-year survival rates of 30% and 5% respectively. Several prognostic factors had been identified for gastric cancer including stage, location, pathological subtype, peritoneal deposits, and HER2-neu over-expression. In this retrospective analysis, we are aiming at identifying the clinicopathological, epidemiological and treatment outcome for patients with advanced gastric cancer. Methods: We analyzed the medical records of advanced gastric cancer patients treated at Ain-Shams university hospital from the period of January 2011 till December 2014. Eighty-one patients were included with thirty-eight paraffin blocks were available for retrospective analysis of HER2-neu status. Results: Median age at presentation was 52 (range 25-81). Fifty-five percent were male (45 patients) and 57% were smokers. Most common primary site was antrum (33.5%).

No abstract

No abstract